Home> #BIGDATAFORBLOODCANCER campaign for clinicians and researchers: April - July 2021.> 2. Transforming High Quality Data into Meaningful evidence for Blood Cancer
May 30, 2021 10:50 - x 00, 0 - 00:00
Big Data are described as having 'transformative potential' – but what exactly is 'Big Data' in healthcare, how and why is HARMONY using it and what does it mean for people with Hematologic Malignancies? Watch our short video series to find out.
Video one: Explaining Big Data and blood cancers: an introduction
This video provides a short introduction to Big Data and illustrates how HARMONY is using such data to accelerate the development of new treatments for Hematologic Malignancies.
Video two: Explaining the need for Big Data
The second video communicates why Big Data are essential for conducting novel, large-scale research that accelerates drug development, regulatory evaluation, access appraisal and treatment strategies in Hematologic Malignancies.
Video three: Explaining ethics, data quality, safety and privacy
When it comes to data anonymization, storage and privacy, HARMONY upholds the highest standards – the final video in our series explains this.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
